PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18358555-0	2008	The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.	Metformin	14-23	serpin family E member 1	Homo sapiens	46-51	
18358555-6	2008	After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in beta cell reserve values of the patients.	Metformin	6-15	serpin family E member 1	Homo sapiens	162-195	
18358555-6	2008	After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in beta cell reserve values of the patients.	Metformin	6-15	serpin family E member 1	Homo sapiens	197-202	
18358555-7	2008	Our results indicated that, metformin addition had beneficial effect on VEGF and PAI-1 levels in obese type 2 diabetic patients under MNT+REP, independent from its" favourable effects on BMI and glycemic control.	Metformin	28-37	serpin family E member 1	Homo sapiens	81-86